Department of Pharmacotherapy & Outcome Science, Virginia Commonwealth University School of Pharmacy, 410 N 12th Street, Richmond, VA 23298, USA.
Pharmacogenomics. 2023 Feb;24(3):173-182. doi: 10.2217/pgs-2022-0160. Epub 2023 Jan 20.
Statins are among the most commonly prescribed medications worldwide. Rosuvastatin is a moderate- to high-intensity statin depending on the prescribed dose. Statin-associated muscle symptoms are the main side effects, contributing to low adherence to statins. The missense variant rs2231142 in affects the functionality of the ABCG2 transporter, altering the pharmacokinetics and pharmacodynamics of rosuvastatin. This special report aims to accentuate the importance of considering the genotype upon prescribing rosuvastatin in high cardiovascular disease risk subgroups, specifically Native Hawaiian and Pacific Islander populations. Based on the reported frequencies of rs2231142 in , it may be justifiable to initiate low-dose rosuvastatin in Samoans relative to Marshallese or Native Hawaiians. Interpopulation differences in pharmacogenetic allele frequencies underscore the need to disaggregate broad population categories to achieve health equity in treatment outcomes.
他汀类药物是全球最常用的药物之一。根据处方剂量,瑞舒伐他汀是一种中高强度的他汀类药物。他汀类药物相关的肌肉症状是主要的副作用,导致他汀类药物的依从性降低。位于 的错义变体 rs2231142 影响 ABCG2 转运蛋白的功能,改变瑞舒伐他汀的药代动力学和药效动力学。本特别报告旨在强调在为高心血管疾病风险亚组(特别是夏威夷原住民和太平洋岛民)开处方瑞舒伐他汀时,考虑 基因型的重要性。基于报告的 rs2231142 在 中的频率,与马绍尔群岛或夏威夷原住民相比,萨摩亚人可能有理由开始使用低剂量的瑞舒伐他汀。人群间药物遗传学等位基因频率的差异强调了需要细分广泛的人群类别,以实现治疗结果的健康公平。